TY - JOUR
T1 - Age-based disparities in statin use for primary prevention in US adults
T2 - National Health and Nutrition Examination Surveys 2013-2020
AU - Zheutlin, Alexander R.
AU - Jacobs, Joshua A.
AU - Derington, Catherine G.
AU - Chaitoff, Alexander
AU - Navar, Ann Marie
AU - Bress, Adam P.
N1 - Publisher Copyright:
© 2023
PY - 2023/9/1
Y1 - 2023/9/1
N2 - Statin use among younger adults at high atherosclerotic cardiovascular disease (ASCVD) risk compared with older adults at the same risk is unclear. We determined prevalent statin use by 10-year ASCVD risk and age among US participants aged 40-75 eligible for risk-indicated primary prevention statins from the 2013-2020 National Health and Nutrition Examination Survey cycles. Among 3,503 participants, statin use by ASCVD risk (5-<7.5%, 7.5-<20%, and ≥20%) was 9.4%, 9.0%, and 12.2% among those age 40-54 compared to 22.0%, 23.9%, and 14.3% among adults 55-64 years and 39.3%, 33.6%, and 38.1% age 65-75 years. After adjusting for sociodemographic and healthcare access, the prevalence ratio (vs. 65-75 years) for statin use among adults with an ASCVD risk of 7.5-<20% age 40-54 years was 0.40 (95% confidence interval [CI] 0.39,0.41) and 0.87 (95% CI 0.87,0.88) for adults 55-64 years. Among high ASCVD-risk adults aged 40-75 years, primary prevention statin use was lower among adults <65 years despite similar ASCVD risk as older adults.
AB - Statin use among younger adults at high atherosclerotic cardiovascular disease (ASCVD) risk compared with older adults at the same risk is unclear. We determined prevalent statin use by 10-year ASCVD risk and age among US participants aged 40-75 eligible for risk-indicated primary prevention statins from the 2013-2020 National Health and Nutrition Examination Survey cycles. Among 3,503 participants, statin use by ASCVD risk (5-<7.5%, 7.5-<20%, and ≥20%) was 9.4%, 9.0%, and 12.2% among those age 40-54 compared to 22.0%, 23.9%, and 14.3% among adults 55-64 years and 39.3%, 33.6%, and 38.1% age 65-75 years. After adjusting for sociodemographic and healthcare access, the prevalence ratio (vs. 65-75 years) for statin use among adults with an ASCVD risk of 7.5-<20% age 40-54 years was 0.40 (95% confidence interval [CI] 0.39,0.41) and 0.87 (95% CI 0.87,0.88) for adults 55-64 years. Among high ASCVD-risk adults aged 40-75 years, primary prevention statin use was lower among adults <65 years despite similar ASCVD risk as older adults.
KW - Age
KW - cardiovascular risk
KW - healthcare disparities
KW - statin
UR - http://www.scopus.com/inward/record.url?scp=85168465320&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85168465320&partnerID=8YFLogxK
U2 - 10.1016/j.jacl.2023.08.005
DO - 10.1016/j.jacl.2023.08.005
M3 - Article
C2 - 37599197
AN - SCOPUS:85168465320
SN - 1933-2874
VL - 17
SP - 688
EP - 693
JO - Journal of Clinical Lipidology
JF - Journal of Clinical Lipidology
IS - 5
ER -